Business News›vykat xr
SEARCHED FOR:
VYKAT XR
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
Soleno Therapeutics has withdrawn its European drug application. This decision stems from its acquirer, Neurocrine Biosciences, prioritizing the United States market. The drug, Vykat XR, treats a rare genetic disorder. Neurocrine's CEO confirmed the focus remains on the U.S. launch. This move aligns with a trend of delayed European launches amid U.S. pricing policy shifts.
Soleno shares jump 33% as Neurocrine expands into metabolic diseases with $2.9 billion buyout
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders.
BACK TO TOP